Concepedia

Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial

Cristina Tassorelli, Krisztián Nagy, Patricia Pozo‐Rosich, Michel Lantéri‐Minet, Sara Sacco, Tomáš Nežádal, Hua Guo, Rosa De Abreu Ferreira, Giovanna Forero, Joel M. Trugman

The Lancet Neurology · 2024 · 75 citations · 20 references

DOI

Concepts

References

20

Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition

Cephalalgia · 2018 · 10.5K citations · Full text

, , +6

Migraine remains second among the world’s causes of disability, and first among young women: findings from GBD2019

Timothy J. Steiner, Lars Jacob Stovner, Rigmor Jensen et al. · The Journal of Headache and Pain · 2020 · 1.1K citations · Full text

, , +6

The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice

Jessica Ailani, Rebecca Burch, Matthew S. Robbins · Headache The Journal of Head and Face Pain · 2021 · 743 citations · Full text

, , +13

Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study

Uwe Reuter, Peter J. Goadsby, Michel Lantéri‐Minet et al. · The Lancet · 2018 · 470 citations · Full text

, , +9

Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial

Michel D. Ferrari, Hans‐Christoph Diener, Xiaoping Ning et al. · The Lancet · 2019 · 434 citations

, , +14